1.25
0.02 (1.63%)
| Penutupan Terdahulu | 1.23 |
| Jumlah Dagangan | 1,529,308 |
| Harga / Jualan (P/S) | 2.52 |
| Harga / Buku (P/B) | 6.90 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -281,733.35% |
| EPS Cair (TTM) | -2.14 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -100.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 113.62% |
| Nisbah Semasa (MRQ) | 0.360 |
| Aliran Tunai Operasi (OCF TTM) | -8.11 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.33 M |
| Pulangan Atas Aset (ROA TTM) | -218.06% |
| Pulangan Atas Ekuiti (ROE TTM) | -737.89% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | BioCardia, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.89 |
|
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 21.66% |
| % Dimiliki oleh Institusi | 4.75% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Pingora Partners Llc | 30 Jun 2026 | 120,382 |
| Wealth Enhancement Advisory Services, Llc | 30 Jun 2026 | 18,500 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ALTMAN PETER | 1.09 | - | 800 | 872 |
| Jumlah Keseluruhan Kuantiti Bersih | 800 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 872 | |||
| Purata Pembelian Keseluruhan ($) | 1.09 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ALTMAN PETER | Pegawai | 03 Sep 2026 | Beli (+) | 800 | 1.09 | 872 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |